Jan Bubenik
Overview
Explore the profile of Jan Bubenik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Reinis M, Simova J, Indrova M, Bieblova J, Bubenik J
Int J Oncol
. 2007 Mar;
30(5):1247-51.
PMID: 17390028
Oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) are potent inducers of anti-tumour immune responses. In this study, we analyzed the capacity of CpG ODN to inhibit the growth of both MHC...
12.
Reinis M, Simova J, Indrova M, Bieblova J, Pribylova H, Moravcova S, et al.
Int J Oncol
. 2007 Mar;
30(4):1011-7.
PMID: 17332942
Loss or downregulation of MHC class I molecules on tumour cells is a common mechanism by which tumours can escape from T-cell mediated immune responses. In this study we have...
13.
Simova J, Bubenik J, Bieblova J, Rosalia R, Fric J, Reinis M
Int J Oncol
. 2006 Nov;
29(6):1567-71.
PMID: 17088998
It is generally accepted that T regulatory cells (T(reg) CD4(+)CD25(+)Foxp3(+)) play an important role in the suppression of tumour immunity. We examined the impact of T(reg) cell depletion with anti-CD25...
14.
Reinis M, Simova J, Bubenik J
Int J Cancer
. 2005 Oct;
118(7):1836-42.
PMID: 16217768
Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) have been described as potent inducers of selected antitumour immune responses and the immunotherapeutic efficacy of CpG ODN has been examined either alone...
15.
Bubenik J, Simova J
Oncol Rep
. 2005 Oct;
14(5):1377-80.
PMID: 16211312
Local recurrences at the site of tumour resection as well as distant micrometastases manifested after surgery represent major problems in oncology. Adjuvant immunotherapy and gene therapy may help to cope,...
16.
Mikyskova R, Bubenik J, Vonka V, Smahel M, Indrova M, Bieblova J, et al.
Int J Oncol
. 2005 Jan;
26(2):521-7.
PMID: 15645139
Malignant transformation of somatic cells followed by selection of the transformed cell populations can give rise to tumours that display an immune escape phenotype, MHC class I deficient neoplasms. Experiments...
17.
Reinis M, Indrova M, Mendoza L, Mikyskova R, Bieblova J, Bubenik J, et al.
Int J Oncol
. 2004 Sep;
25(4):1165-70.
PMID: 15375569
Dendritic cell (DC)-based vaccines are being intensively investigated for the treatment of a variety of human neoplasms. However, little attention has until now been paid to the use of DC-based...
18.
Bubenik J
Int J Oncol
. 2004 Jul;
25(2):487-91.
PMID: 15254748
Malignant conversion and subsequent in vivo selection can give rise to the cell populations that show stable expression of an immune escape phenotype, MHC class I deficient neoplasms. Deficiencies associated...
19.
20.
Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, et al.
Int J Oncol
. 2003 Dec;
24(1):161-7.
PMID: 14654953
Moderately immunogenic HPV16-associated tumours TC-1 (MHC class I+, HPV16 E6/E7+, G12V Ha-ras+) and MK16/1/IIIABC (MK16, MHC class I-, HPV16 E6/E7+, G12V Ha-ras+), both of the H-2b haplotype and transplanted in...